Summary
Insulin glargine, marketed under the names Lantus among others, is a long-acting basal insulin analogue, given once daily to help control the blood sugar level of those with diabetes. It consists of microcrystals that slowly release insulin, giving a long duration of action of 18 to 26 hours, with a "peakless" profile (according to the insulin glargine package insert).
The global Insulin Glargine market will reach xxx Million USD in 2019 with CAGR xx% 2019-2025. The main contents of the report including:
Global market size and forecast
Regional market size, production data and export & import
Key manufacturers profile, products & services, sales data of business
Global market size by Major Application
Global market size by Major Type
Key manufacturers are included based on company profile, sales data and product specifications etc.:
Sanofi-Aventis
Ganlee
Biocon
Major applications as follows:
Treat type 1 diabetes
Treat type 2 diabetes
Major Type as follows:
Single Dose Vial
Pre-filled Syringe
Regional market size, production data and export & import:
Asia-Pacific
North America
Europe
South America
Middle East & Africa
Summary:
Get latest Market Research Reports on Insulin Glargine . Industry analysis & Market Report on Insulin Glargine is a syndicated market report, published as Global Insulin Glargine Market Data Survey Report 2013-2025. It is complete Research Study and Industry Analysis of Insulin Glargine market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.